这五种物质被归类为一级管制药物——裸盖菇素和脱磷酸裸盖菇素(存在于蘑菇中)、二甲基色胺(DMT)和伊博格碱(存在于植物中)，以及墨斯卡灵(存在于仙人掌中)。On Tuesday, Massachusetts voters will decide whether the state will legalize a psychedelic compound, psilocybin, found in 'magic mushrooms,' and related stocks are worth paying attention to.
According to the Financial Community APP, on Tuesday, Massachusetts voters will decide whether the state will legalize a psychedelic compound, psilocybin, found in 'magic mushrooms.' This change will enable individuals to access this substance for mental health therapeutic purposes. If the vote is successful, Massachusetts will become the third state, following Oregon and Colorado, to legalize certain psychedelics.
It is understood that if voters vote in favor of Question 4 in November, individuals aged 21 and over will be able to legally use 5 psychedelics. Additionally, a regulatory commission and an advisory committee will be established. These substances will not be sold by retailers, but by licensed professionals at psychedelic therapy centers.
These five substances are classified as Schedule I controlled substances - psilocybin and psilocin (found in mushrooms), dimethyltryptamine (DMT) and ibogaine (found in plants), and mescaline (found in cacti).
However, voters seem to have differing opinions. According to a poll conducted by the University of Massachusetts Amherst and WCVB television station on 700 residents, 43% of respondents either support or oppose legalization.
Many experts have expressed concerns about these risks. According to a study by the Tufts University Center for State Policy Analysis, ibogaine can lead to acute heart problems, DMT may have lasting effects on the nervous system, while 'psilocybin and mescaline risks seem to be lower.'
The Massachusetts Psychiatric Society, the American Psychiatric Association, and the Massachusetts College of Emergency Physicians oppose the voting issue. The American Psychological Association states, 'Clinical treatment should be determined by scientific evidence, not by voting initiatives or public sentiment.'
However, many medical professionals have expressed their support. They said: "Issue 4 will establish infrastructure to promote safety and enhance public understanding of psychedelics."
Related stocks include Mind Medicine (MNMD.US), Compass Pathways (CMPS.US), Cybin (CYBN.US), Atai Life Sciences (ATAI.US), Enveric Bio (ENVB.US), Revive Therapeutics (RVVTF.US), Bright Minds Biosciences (DRUG.US), GH Research (GHRS.US), Clearmind Medicine (CMND.US).